Friday, 15 May - Online Workshop Schedule
All session and presentation times are in the Pacific Time Zone and are subject to change. Each session day begins at 08:00, PDT (15:00, GMT/UTC).
Not certain how to convert times to your specific time zone; just click here.
Presenting author is underlined; presenters are subject to change.
Friday, 15 May 2020 | |
---|---|
08:00 – 15:00 | |
08:00 | Welcome |
08:05 | Molecular Therapies for Vascular Malformations: Rapamycin and Beyond │ Adrienne Hammill (United States), Emmanuel Seront (Belgium) |
Scientific Session 5 (08:40 - 09:40) | |
Category: Hemangioma/Tumor | |
08:40 |
Sleep behavior during propranolol treatment for infantile hemangioma – a prospective, controlled study │ Martin Theiler (Switzerland), Sarah F. Schoch, Lisa Weibel, Susanne von der Heydt, Agnes Schwieger-Briel, Alexandra Smith, Isabelle Luchsinger, Kristin Kernland-Lang, Regula Waelchli, Kathrin Neuhaus, Ralph Gnannt, Nicole Knoepfel and Salome Kurth |
08:47 |
Nadolol versus Propranolol in Children with Infantile Hemangioma: A Randomized, Controlled, Double-blinded, Non-inferiority Trial │ Elena Pope (Canada), Irene Lara-Corrales, Carmen Liy-Wong and Beth Drolet |
08:54 |
Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol │ Francois Moisan (France), Sandra Oucherif, Priscilla Kaulanjan-Checkmodine, Sorilla Prey, Christine Leaute-Labreze, Hamid Rezvani and Alain Taïeb |
09:01 |
Investigation of the genetic underpinnings of infantile hemangioma using a ~750 gene NGS panel and exome sequencing │ Whitney Wooderchak-Donahue (United States), Philippe Szankasi, Ashini Bolia, Josue A. Flores Daboub, Alice Frigerio, Devin Close, Hunter Best, J. Fred Grimmer, David A. Stevenson and Pinar Bayrak-Toydemir |
09:08 | Mapping of Segmental and Partial Segmental Hemangiomas of the Face and Scalp │ Anita Haggstrom (United States), Alyson Endicott, Sarah Chamlin, Beth A. Drolet, Kristin Holland, Anthony Mancini, Dawn Siegel and Ilona J. Frieden |
09:15 |
The Coexistence of Upper and Lower Body Segmental Hemangiomas: Patterns and Pathogenesis │ Leila Shayegan (United States), Ilona Frieden, Olivia Davies, Beth Drolet, Dawn Siegel, Sarah Chamlin, Sheilagh Maguiness, Julie Powell and Maria Garzon |
09:22 |
Location of infantile hemangioma is a predictor of volumetric sequelae after involution │ Shih-Jen Chang (China), Wenxin Yu, Yifei Gu, Yue Han, Yin Shang, Lei Chang, Yunbo Jin, Gang Ma, Yajing Qiu and Xiaoxi Lin |
09:29 |
Midanaphase propranolol-resistant infantile hemangiomas │ Lei Chang (China), Qianyi Chen, Zhang Yu, Yajing Qiu, Zongan Chen and Xiaoxi Lin |
Break - Non-CME Activity | |
Scientific Session 6 (09:55 - 11:15) | |
Categories: Hemangioma/Tumor, Potpourri/Varied, Medical/Mixed | |
09:55 |
Long-term outcomes of PHACE syndrome patients: A follow-up of adolescent and adult patients │ Maria Cossio (Spain), Josée Dubois, Catherine McCuaig, Sandra Ondrejchak and Julie Powell |
10:02 |
Arterial Spin-Labeled Perfusion for PHACE Syndrome │ Mark Mamlouk (United States), Luca Caschera, Arastoo Vossough, Mohit Maheshwari and Christopher Hess |
10:09 |
Infantile Hemangioma Ulceration in the Era of Beta-Blockers │ Esteban Fernandez Faith (United States), Sonal Shah, Patricia Witman, Katya Harfmann, Flora Frascari, Francine Blei, Elena Pope, Anwar Alsumait, Deepti Gupta, Isabela Covelli, Jenna Streicher, Colleen Cotton, Megha Tollefson, Henry Nguyen, Raegan Hunt and Ilona J. Frieden |
10:16 |
Liver Injury Associated with Hepatic Congenital Hemangioma Mimicking Acute Liver Failure in a Neonate │ Catharine Garland (United States), Lisa Arkin, Jason Pinchot, Kara Gill, Daniel O'Connell, Istvan Danko, Matthew Harer, Shelly Cook, Darya Buehler and Adam Bauer |
10:22 |
Congenital presentation of Cerebral Cavernous Malformation 3 │ Shoshana Greenberger (Israel), Leah Leibovitch, Omer Bar-Yosef and Victor Martinez-Glez |
10:28 | Genetic Variants in Phacomatosis Pigmentovascularis │ Ren Cai (China), Qingqing Cen, Gang Ma, Fatao Liu, Yun Liu and Xiaoxi Lin |
10:34 |
Vascular Malformations – Comparative analysis of the surrounding tumor microenvironment and its impact on vasculogenesis │ Caroline Seebauer (Germany), Johanna Ganzenmüller, Thomas Kühnel, Christopher Bohr and Veronika Vielsmeier |
10:40 |
Congenital Aberrant Muscular Overgrowth of Hands and Feet. A Multicentric Study of Case Series │ Carlos Delgado-Miguel (Spain), Antonio Jesús Muñoz-Serrano, Miriam Miguel-Ferrero, Paloma Triana Junco, Víctor Martínez-González, María del Carmen Boente, Antonio Torrelo and Juan Carlos Lopez-Gutierrez |
10:46 |
cfDNA NGS-Liquid Biopsy: A new revolutionary approach for Klippel-Trenaunay Syndrome │ Anna Maria Pinto, Maria Palmieri (Italy), Aurora Currò, Laura Di Sarno, Elisa Frullanti, Annarita Giliberti, Chiara Fallerini, Francesco Molinaro, Laura Di Blasio, Luca Primo, Massimo Vaghi and Alessandra Renieri |
10:52 |
Further Elucidation of the Molecular Mechanisms of Vascular Malformations and Overgrowth: PIK3R1 Mosaic Variation │ Olivia Davies (United States), Eulalia Baselga, Nicole Bender, Leslie Biesecker, Heather Ciliberto, Catherine Cottrell, Carrie Coughlin, Ilona J. Frieden, Maria Garzon, Anita Haggstrom, Catherine McCuaig, Julie Powell, Megha Tollefson, Michael Zimmermann and Beth Drolet |
10:58 |
Next-generation Sequencing of Circulating tumor DNA (Ct-DNA) in Venous Malformation (VM), Lymphatic Malformation (LM) and Lymphatico-venous malformations (LVM) │ Ren Cai (China), Hao Gu, Hui Chen, Yun Liu and Xiaoxi Lin |
11:04 |
Presentations of Congenital Extrahepatic Portosystemic Shunts in Patients with PIK3CA-Related Overgrowth Spectrum (PROS) │ David Mitchell (United States), Elizabeth Nieman, Mitchell Pet, Susan Bayliss, Marcia Willing, Maithilee Menezes, Carlos Guevara, Kamlesh Patel, Leonid Shmuylovich, Janis Stoll, David Wilson, Denise Adams, Eric Monroe and Christopher Malone (United States) |
11:10 |
Prospective Phase III Clinical Trial VASE. Mid-term Results on Efficacy: Sirolimus Sensitivity and Genetic Profiles │ Emmanuel Seront (Belgium), An Van Damme, Annouk Bisdorff Bresson, Philippe Orcel, Anne Dompmartin-Blanchère, Marie Antoinette Sevestre, Patrice Forget, Philippe Clapuyt, Frank Hammer, Catherine Legrand, Miikka Vikkula and Laurence M. Boon |
Scientific Session 7 (11:45 - 13:15) | |
Category: Medical/Mixed, Capillary Malformations | |
11:45 |
Severe adverse events (SAE) during Sirolimus therapy for vascular anomalies: Toxicity during “off label” use │ Jochen Rössler (Switzerland), Eulalia Baselga, Victoria Davila, Veronica Celis, Andrea Diociaiuti, Maya El Hachem, Christof Hanke, Wolfgang Loichinger, Charlotte M. Niemeyer and Friedrich Kapp |
11:51 |
Analyzing Coagulation Dynamics During Treatment of Vascular Malformations with Thromboelastography (TEG) │ Joana Mack (United States), Beverly Spray, C. D'ann Pierce, Gresham T. Richter, Richard Nicholas, Spencer Lewis and Shelley Crary |
11:57 |
Aberrant venous anatomy as a risk factor for thromboembolic events in patients with Klippel-Trénaunay Syndrome: case-control study within a cohort-study │ Carine van der Vleuten (The Netherlands), Bas Verhoeven, Lilly Zwerink, Richard Praster and Maroeska Te Loo |
12:03 | A Case of Aggressive Lymphoma in Gorham Stout Disease Treated with mTOR Inhibition │ Sara Kreimer (United States) and Michael Jeng |
12:09 |
Multisystemic Congenital Disseminated Pyogenic Granuloma: Clinical and Imaging Characterization of a Rare Disorder │ Mohammed Alomari, Wibke Uller, Gulraiz Chaudry, Harry Kozakewich, Arin Greene, Steven Fishman, Marilyn Liang, John Mulliken, Denise Adams, Cindy Kerr and Ahmad Alomari (United States) |
12:15 | Segmental Undergrowth associated with vascular anomalies: The great forgotten │ Victor Martinez-Glez (Spain), Paloma Triana, Lara Rodriguez Laguna, Begoña Hurtado and Juan Carlos Lopez-Gutierrez |
12:21 |
FAVA vs PHOST- A case review from clinical, radiologic and histopathologic perspectives │ Catherine Tchanque-Fossuo, Jaimie Y. Lin (United States), Anna Fabre, Shelly Stepenaskie, Jessica B. Williams and Aimee C. Smidt |
12:27 |
Retrospective Review of Neurological Manifestations in 189 Patients Diagnosed with CLOVES Syndrome │ Ian Erkkila (United States), Camilo Jaimes Cobos, Richard P. Greiwe, Meghan O'Hare, Steven Fishman, Ahmad Alomari, Cameron Trenor and Denise Adams |
12:33 |
Venous malformations have COLLAGEN IV deposition defects associated with increased endothelial cell death │ Andrew I. Zeiler, Michael J. Schonning, Carrie J. Shawber and June K. Wu (United States) |
12:39 |
Classification of lower extremity venous malformations and the risk of intra-articular knee involvement │ Krystal Jones (United States), Kristen Corey, Anna Cristina Garza-Mayers, Samantha Spencer, John Mulliken, Rush Chewning and Marilyn Liang |
12:45 |
Diagnostic utility of lesional color when differentiating Infantile Hemangiomas from Port-Wine Stains in Infants less than 3 months old │ Kathleen O'Brien (United States), Ilona J. Frieden, Alexander Zeymo, Jelena Vasic, Robert Silverman, Gerald Goldberg and Cynthia Carver DeKlotz |
12:51 | Expression of Cathepsins B, D and G in Hypertrophic Port Wine Stains │ Sabrina Koh (New Zealand), Helen Brasch, Josie Patel, Nicholas Bockett, Erin Paterson, Paul Davis and Swee Tan |
12:57 | Do Frequent PDL Treatments for Port Wine Stains Improve the Final Outcome? │ Assi Levi (Israel), Igor Snast and Moshe Lapidoth |
13:03 (Difficult Case) |
Lower extremity AVM in a patient with CM-AVM syndrome and cardiac compromise: Successful management with trametinib │ Siobhan Flanagan, Michael Murati, Timothy Moss, Christina Boull, Erin McGough, Rebecca Ameduri, Denise Adams, Brenda Weigel and Sheilagh Maguiness (United States) |
Break - Non-CME Activity (13:15 - 13:30) | |
Scientific Session 8 (13:30 - 14:45) | |
Categories: AVM | |
13:30 (Difficult Case) |
Management challenges of a large upper extremity vascular malformation in a patient with Capillary Malformation/Arteriovenous Malformation (CM-AVM) syndrome │ Michael Zobel (United States), Willieford Moses, Ashley Walther, Donna Nowicki, Lori Howell, Chadi Zeinati, Joseph Miller and Dean Anselmo |
13:38 | Trametinib as a promising therapeutic option for treating vascular lesions in a novel arteriovenous malformation mouse model │ Ha-Long Nguyen, Delphine Nolf and Miikka Vikkula (Belgium) |
13:46 |
Thalidomide is an Efficient Treatment for Symptomatic and/or Life-Threatening Arteriovenous Malformations │ Laurence M. Boon (Belgium), Liliane Marot, Frank Hammer, Anne Jeanjean, Valerie Dekeuleneer, Julien Coulie, Marleen Tadler, Philippe Clapuyt, Anne-Christine Bataille, Anne Dompmartin and Miikka Vikkula |
13:54 | Expression of Induced Pluripotent Stem Cell Markers in Extracranial Arterio-venous Malformation │ Claire Luke-Krishnan (New Zealand), Helen Brasch, Josie Patel, Nicholas Bockett, Erin Paterson, Paul Davis, Imogen Roth and Swee Tan |
14:02 |
Cobb syndrome: Genomic identification of an activating KRAS mutation, targeted medical therapy, and use of Phase Contrast MRA to gauge response to treatment │ Kristin Shimano (United States), Emily Edwards, Andrew Phelps, Daniel Cooke, Matthew Zapala, Heather Fullerton, Jason Pomerantz and Ilona J. Frieden |
14:10 | RASA1 mosaic mutations in patients with capillary malformation - arteriovenous malformation │ Nicole Revencu (Belgium), Elodie Fastré, Marie Ravoet, Raphael Helaers, Pascal Brouillard, Annouk Bisdorff Bresson, Clara Chung, Marion Gerard, Veronika Dvorakova, Alan Irvine, Laurence M. Boon and Miikka Vikkula |
14:18 |
Somatic Arteriovenous Malformation MAP2K1 Mutation Causes Cartilage Overgrowth by a Cell Non-Autonomous Mechanism │ Christopher Sudduth (United States), Dennis Konczyk, Jeremy Goss, Patrick Smits, Alyaa Al-ibraheemi and Arin Greene |
14:26 |
Management of Periorbital Arteriovenous Malformation: Trans-ophthalmic Artery Onyx Embolisation Followed by Ethanol Embolotherapy │ Xi Yang (China), Yunbo Jin, Chen Hua, Hao Gu, Yuanbo Li, Hecheng Jia, Xiaoxi Lin |
R. Schobinger Tribute, ISSVA Election Results, Closing & Thank You (14:35- 15:00) | |